Celldex Therapeutics, Inc CLDX
$42.61
-5.04%
at last close
Analyst Consensus
- Consensus Rating
- Buy (11 Buy · 1 Hold · 0 Sell)
- Average Price Target
- $56.42
- Implied Upside
- +32.4%
- Price Target Range
- $34.00 – $100.00
- Analysts (12 mo)
- 12
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-07 | Morgan StanleyJudah Frommer |
Maintains | Overweight | $40 → $46 |
| 2026-08-07 | BarclaysEtzer Darout |
Maintains | Overweight | $48 → $53 |
| 2026-07-29 | Wells FargoDerek Archila |
Maintains | Overweight | $48 → $72 |
| 2026-07-22 | Wells FargoDerek Archila |
Maintains | Overweight | $54 → $48 |
| 2026-07-22 | Morgan StanleyJudah Frommer |
Maintains | Overweight | $44 → $40 |
| 2026-07-22 | Cantor FitzgeraldKristen Kluska |
Maintains | Overweight | $67 → $61 |
| 2026-07-22 | Canaccord GenuityEdward Nash |
Maintains | Buy | $62 → $60 |
| 2026-07-20 | GuggenheimYatin Suneja |
Maintains | Buy | $90 → $100 |
| 2026-06-15 | HC Wainwright & Co.Joseph Pantginis |
Reiterates | Buy | $42 |
| 2026-06-10 | UBSDavid Dai |
Maintains | Buy | $38 → $45 |
| 2026-05-13 | Wells FargoDerek Archila |
Maintains | Overweight | $38 → $54 |
| 2026-05-08 | BarclaysEtzer Darout |
Maintains | Overweight | $45 → $48 |
| 2026-04-20 | BarclaysEtzer Darout |
Upgrades | Underweight → Overweight | $24 → $45 |
| 2026-03-02 | Goldman SachsRichard Law |
Maintains | Neutral | $30 → $34 |
| 2026-02-26 | StifelAlex Thompson |
Reiterates | Buy | $58 → $68 |
| 2025-12-17 | BarclaysEtzer Darout |
Maintains | Underweight | $21 → $24 |
| 2025-11-11 | BarclaysEtzer Darout |
Maintains | Underweight | $25 → $21 |
| 2025-10-21 | MizuhoJoseph Catanzaro |
Initiates coverage on | Outperform | $48 |
| 2025-10-13 | BarclaysEtzer Darout |
Initiates coverage on | Underweight | $25 |
| 2025-09-17 | Canaccord GenuityEdward Nash |
Maintains | Buy | $62 |
| 2025-08-20 | Wells FargoDerek Archila |
Maintains | Overweight | $44 → $38 |
| 2025-08-20 | CitigroupDavid Lebowitz |
Maintains | Buy | $56 → $48 |
| 2025-08-20 | Canaccord GenuityEdward Nash |
Maintains | Buy | $64 → $62 |
| 2025-08-20 | HC Wainwright & Co.Joseph Pantginis |
Maintains | Buy | $50 → $42 |
| 2025-06-16 | HC Wainwright & Co.Joseph Pantginis |
Reiterates | Buy | $50 |
| 2025-06-13 | HC Wainwright & Co.Joseph Pantginis |
Reiterates | Buy | $50 |
| 2025-05-09 | UBSTrung Huynh |
Maintains | Buy | $44 → $38 |
| 2025-05-09 | Goldman SachsRichard Law |
Maintains | Neutral | $36 → $31 |
| 2025-05-09 | Morgan StanleyJudah Frommer |
Maintains | Overweight | $46 → $43 |
| 2025-05-09 | HC Wainwright & Co.Joseph Pantginis |
Maintains | Buy | $80 → $50 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $42.61
- Market Cap
- $3.52 billion
- 52-Week Range
- $19.72 – $45.14
- Average Volume
- 965K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.